These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35766333)

  • 1. TTN mutations predict a poor prognosis in patients with thyroid cancer.
    Han X; Chen J; Wang J; Xu J; Liu Y
    Biosci Rep; 2022 Jul; 42(7):. PubMed ID: 35766333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of disulfidptosis-associated genes and characterization of immune cell infiltration in thyroid carcinoma.
    Song S; Zhou J; Zhang L; Sun Y; Zhang Q; Tan Y; Zhou X; Yu J
    Aging (Albany NY); 2024 Jun; 16(11):9753-9783. PubMed ID: 38836761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of hub genes in thyroid carcinoma to predict prognosis by integrated bioinformatics analysis.
    Pan Y; Wu L; He S; Wu J; Wang T; Zang H
    Bioengineered; 2021 Dec; 12(1):2928-2940. PubMed ID: 34167437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
    Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
    BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioinformatics analysis for the identification of Sprouty-related EVH1 domain-containing protein 3 expression and its clinical significance in thyroid carcinoma.
    Zhang X; Meng X; Wang P; Luan C; Wang H
    Sci Rep; 2024 Feb; 14(1):4549. PubMed ID: 38402263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and validation of a TTN mutation associated immune prognostic model for evaluating immune microenvironment and outcomes of gastric cancer: An observational study.
    Chen R; Yao Z; Jiang L
    Medicine (Baltimore); 2024 Jul; 103(29):e38979. PubMed ID: 39029079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis and therapy in thyroid cancer by gene signatures related to natural killer cells.
    Jin Z; Han Y; Zhang J; Liu Z; Li R; Liu Z
    J Gene Med; 2024 Jan; 26(1):e3657. PubMed ID: 38282150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a Prognostic 3-Gene Risk Prediction Model for Thyroid Cancer.
    Zhao H; Zhang S; Shao S; Fang H
    Front Endocrinol (Lausanne); 2020; 11():510. PubMed ID: 32849296
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of prognostic biomarkers related to the tumor microenvironment in thyroid carcinoma.
    Du JW; Li GQ; Li YS; Qiu XG
    Sci Rep; 2021 Aug; 11(1):16239. PubMed ID: 34376710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen-related genes for thyroid cancer prognosis, immune infiltration, staging, and drug sensitivity.
    Zhang L; Zhou M; Gao X; Xie Y; Xiao J; Liu T; Zeng X
    BMC Cancer; 2023 Oct; 23(1):1048. PubMed ID: 37907864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy.
    Hong K; Cen K; Chen Q; Dai Y; Mai Y; Guo Y
    Front Immunol; 2023; 14():1128390. PubMed ID: 36761753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of plasma complement factor B (CFB) in thyroid carcinoma.
    Wu P; Shi J; Sun W; Zhang H
    Bioengineered; 2021 Dec; 12(2):12854-12866. PubMed ID: 34898340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration and validation of key genes associated with early lymph node metastasis in thyroid carcinoma using weighted gene co-expression network analysis and machine learning.
    Liu Y; Yin Z; Wang Y; Chen H
    Front Endocrinol (Lausanne); 2023; 14():1247709. PubMed ID: 38144565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer.
    Zhang L; Yu S; Hong S; Xiao X; Liao Z; Li Y; Xiao H
    BMC Med Genomics; 2023 Oct; 16(1):234. PubMed ID: 37798795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated PDE4C level serves as a candidate diagnostic biomarker and correlates with poor survival in thyroid carcinoma.
    Wang Y; Zhang Y; Li Y; Huang J
    Sci Rep; 2024 Mar; 14(1):6813. PubMed ID: 38514754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of Potential Molecular Subtypes and Signatures of Thyroid Carcinoma Based on Aging-related Gene Analysis.
    Li Z; Jia LI; Zhou HR; Zhang LU; Zhang M; Lv J; Deng ZY; Liu C
    Cancer Genomics Proteomics; 2024; 21(1):102-117. PubMed ID: 38151291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key molecules associated with thyroid carcinoma prognosis: A study based on transcriptome sequencing and GEO datasets.
    Bai M; Ke S; Yu H; Xu Y; Yu Y; Lu S; Wang C; Huang J; Ma Y; Dai W; Wu Y
    Front Immunol; 2022; 13():964891. PubMed ID: 36059514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSPA5 is a prognostic biomarker correlated with immune infiltrates in thyroid carcinoma.
    Dong W; Du D; Huang H
    Endokrynol Pol; 2022; 73(4):680-689. PubMed ID: 36059163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A biomarker and molecular mechanism investigation for thyroid cancer.
    Xie K
    Cent Eur J Immunol; 2023; 48(3):203-218. PubMed ID: 37901864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mining Prognostic Biomarkers of Thyroid Cancer Patients Based on the Immune-Related Genes and Development of a Reliable Prognostic Risk Model.
    Fei H; Han X; Wang Y; Li S
    Mediators Inflamm; 2023; 2023():6503476. PubMed ID: 37554551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.